It was reported on (b)(6) 2019 a patient underwent a double valve replacement, using a trifecta gt aortic valve for the aortic valve replacement (avr) and an epic biocor mitral valve for the mitral valve replacement (mvr).On an unknown date it was discovered that the patient had developed aortic and mitral regurgitation.On (b)(6) 2022, the patient underwent a redo double valve replacement surgery.Upon explant, the epic mitral valve was examined and it appeared that the leaflet had become "thinner" and a hole was observed.Upon explant of the trifecta valve, pannus and a tear was observed on the non-coronary cusp.The patient received two non-abbott devices.It was reported that the patient remained stable throughout the procedure.At the time of report the patient was still in the hospital but recovering well.No additional information has been provided.
|
Explant was reported due to aortic regurgitation, a hole in the cusp, and thinning tissue.The investigation found that cusp 1 was torn.The base of all three cusps had thinning and loss of collagen fibers.Cusp 3 had a thin layer of fibrin.There was no acute inflammation or significant calcifications.The device history record was reviewed to ensure that each manufacturing and inspection operation was performed and the product met all specifications.In the absence of any calcification or evidence for infection, the reported event is consistent with a non-calcific leaflet tear.A non-calcific leaflet tear is a form of structural valve deterioration (svd), which is a well-known complication from valve replacement surgery.A non-calcific leaflet tear is commonly attributed to increased operational leaflet stress but may also be related to biological factors which result in tissue degeneration characterized by loss of collagen.In this case, histological evaluation did demonstrate loss of collagen at the tear site, which could have contributed to the formation of the tear.There is no indication of a product quality issue with regards to manufacture design or labeling.
|